Lung Cancer Trials Ask AI to find trials
TerminatedNot applicableNCT04040244
Official study title

Exhaled Breath Analysis to Predict Risk of Symptomatic Pneumonitis

Study summary

This is a prospective pilot study investigating exhaled breath condensate analyses to quantify the variability over time of various biomarkers associated with symptomatic pneumonitis.

Ask AI to explain this study
Start here

Key things to know

Main goalDiagnostic

This describes the study’s primary purpose.

What is being studiedExhaled Breath Collection and Blood sample

The study team can explain what participation involves.

Who it may be forLocally advanced

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Oct 11, 2023 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Wake Forest University Health Sciences

Study sponsor

01
Study overview

What this study is about

Purpose
Diagnostic
Study type
Interventional
Phase
Not applicable
Sponsor
Wake Forest University Health Sciences
Interventions being studied
Other: Exhaled Breath Collection; Other: Blood sample
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Disease setting
Locally advanced→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Age greater than or equal to 18 years old.
  • Clinically diagnosed or suspected Stage III non-small cell lung cancer to be treated with chemoradiotherapy as part of cancer treatment, as determined by the treating clinician.
  • Plan for treatment with definitive radiotherapy (≥60 Gy) with concurrent chemotherapy at the discretion of the treating radiation and medical oncologists.
  • Willing and able to tolerate exhaled breath collection.
  • Able to provide informed consent.
Reasons someone may not be able to joinExclusion criteria
  • Systemic (oral, intravenous or intramuscular) corticosteroid use for any reason within 5 days of registration.
  • Prior radiotherapy directed at the chest (thoracic inlet superiorly to diaphragm inferiorly).
  • Any systemic antibiotic use within 2 weeks of registration.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Wake Forest Baptist Comprehensive Cancer CenterWinston-Salem, North Carolina

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 11, 2023. Always confirm current availability with the study team.

View original record ↗